Denali Therapeutics Inc. (DNLI) FY2025 10-K Annual Report
Denali Therapeutics Inc. (DNLI) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on Feb 26, 2026. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
Denali Therapeutics Inc. FY2025 10-K Analysis
Business Overview
- • Core business: Developing biotherapeutics using proprietary TransportVehicle™ (TV) technology to cross blood-brain barrier and treat neurodegenerative and lysosomal storage diseases
- • New emphasis: Advancing two near-launch products—tividenofusp alfa for MPS II (Hunter syndrome) and DNL126 for MPS IIIA—with $1B+ initial market opportunity
- • Strategic shift: Transitioning from platform validation to commercial delivery with D3X3 strategy targeting two commercial brands, five clinical proof-of-concept readouts, and 4-6 new clinical programs (2026-2028)
- • Quantitative highlight: Over 200 clinical trial participants dosed with 11,000+ TV-enabled therapeutic doses; commercial readiness established including dedicated commercial team
- • Noteworthy fact: April 5, 2026 PDUFA date for tividenofusp alfa’s FDA accelerated approval BLA with expected first product launch, despite regulatory review extension due to major amendment
Management Discussion & Analysis
- • Revenue recognition requires significant judgment on collaboration arrangements; no material revenue true ups reported to date
- • Research & development (R&D) expenses mainly external, based on estimates from progress reports; no material true ups in R&D expenses or reimbursements to date
- • Increasing judgment required for R&D expense estimates due to more extensive late-stage clinical trials
- • R&D funding payments recorded as liability and offset to R&D expenses; no material true ups in funding recognition
- • No specific revenue, profitability, segment performance, cash flow, or forward-looking guidance disclosed in this section
Risk Factors
- • FDA regulatory risk: Phase 2/3 HEALEY ALS trial of DNL343 missed primary endpoints in Jan 2025, risking program discontinuation or delays
- • Geopolitical/macro exposure: $966.2M cash runway through 12+ months threatened by inflation, tariffs, foreign currency risks, and economic downturns
- • Supply chain: Reliance on third parties for clinical trial manufacturing and raw materials may cause shortages or delays in product supply
- • Competition: Risk from other neurodegenerative disease biotech firms as limited approved therapies increase pressure to demonstrate efficacy first
- • Financial risk: Accumulated deficit $2.05B with $512.5M net loss in 2025; no product revenue, ongoing need for additional financing to continue development
Denali Therapeutics Inc. FY2025 Key Financial MetricsXBRL
Revenue
$0
Net Income
-$513M
▼ -21.2% YoY
ROE
-50.6%
▼ -1618bp YoY
Total Assets
$1.1B
▼ -16.7% YoY
EPS (Diluted)
$-2.97
▼ -15.6% YoY
Operating Cash Flow
-$413M
▼ -18.7% YoY
Source: XBRL data from Denali Therapeutics Inc. FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Denali Therapeutics Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.